Bibliography
- NADJI M, GOMEX-FERNANDEZ C, GANJEL-AZAR, MORALES AR: Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. (2005) 123(1):21-27.
- Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group (EBCTG). Lancet (1998) 351(9114):1451-1467.
- HAYES DF: Tamoxifen: Dr Jekyll and Mr. Hyde? J. Natl. Cancer Inst. (2004) 96(12):895-897.
- POWLES TJ, HICKISH T, KANIS JA, TIDY A, ASHLEY S: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. (1996) 14(1):78-84.
- HARADA N, UTSUMI T, TAKAGI Y: Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinoogenesis. Proc. Natl. Acad. Sci. USA (1993) 90(23):11312-11316.
- ZHAO Y, NICHOLS JE, BULUN SE, MENDELSON CT, SIMPSON ER: Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. J. Biol. Chem. (1995) 270(27):16449-16457.
- KARAER O, ORUC S, KOYUNCU FM: Aromotase inhibitors: possible future applications. Acta Obstet. Gynecol. Scand. (2004) 83(8):699-706.
- NAKATA T, TAKASHIMA S, SHIOTSU Y et al.: Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. (2003) 86(3-5):455-460.
- OSBORNE CK: Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. (1998) 339(22):1609-1618.
- SMITH IE, DOWSETT M: Aromatase inhibitors in breast cancer. N. Engl. J. Med. (2003) 348(24):2431-2442.
- Femara®: Letrozole tablets package insert. Novartis (2001); Jan (T2001-03):8901032.
- MITWALLY MF, CASPER RF: Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr. Opin. Obstet. Gynecol. (2002) 14(3):225-263.
- STEIN RC, DOWSETT M, HEDLEY A, GAZET JC, FORD HT, COOMBES RC: The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer (1990) 62(4):679-683.
- DOWSETT M, STEIN RC, COOMBES RC: Aromatization inhibition alone or in combination with FnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. (1992) 43(1-3):155-159.
- CELIO L, MARTINETTI A, FERRARI L et al.: Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. (1999) 19(3B):2261-268.
- JEE BC, KU SY, SUH CS, KIM KC, LEE WD, KIM SH: Use of letrozole versus clomiphene citrate combined with gonadotropins in intrauterine insemination cycles: a pilot study. Fertil. Steril. (2006) 85(6):1774-1777.
- VERPOEST WM, KOLIBIANAKIS E, PAPANIKOLAOU E, SMITZ J, VAN STEIRTEGHEM A, DEVROEY P: Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reprod. Biomed. Online (2006) 13(2):166-172.
- AL-FADHLI R, SYLBESTRE C, BUCKETT W, TAN SL, TULANDI T: A randomized trial of superovulation with two different doses of letrozole. Fertil. Steril. (2006) 85(1):161-164.
- ATAY V, CAM C, MUCHU M, CAM M, KARATEKE A: Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J. Int. Med. Res. (2006) 34(1):73-76.
- BEGUM MR, QUADIR E, BEGUM A, BEGUM RA, BEGUM M: Role of aromatase inhibitor in ovularion induction in patients with poor response to clomiphene citrate. J. Obstet. Gynaecol. Res. (2006) 32(5):502-506.
- OKTAY K, HOURVITZ A, SAHIN G et al.: Letrozole reduces estrogen and gonadotropins exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab. (2006) 91(10):3885-3890.
- SCOTT LJ, KEAM SJ: Letrozole: in postmenopausal hormone-responsive early-stage breast cancer. Drugs (2006) 66(3):353-362.
- LONNING P: Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin. Pharmacokinet. (2003) 42(7):619-631.
- DOWSETT M, SMITH IE, EBBS SR et al.: Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res. (2006) 12(3 Suppl.):S1024-S1030.
- INGLE JN, SUMAN VJ, JOHNSON PA et al.: Evaluation of tamozifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin. Cancer Res. (1999) 5(7):1642-1649.
- GEISLER J, HAYNES B, ANKER F, DOWSETT M, LONNING PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. (2002) 20(3):751-757.
- ROSE C, VTORAYA O, PLUZANSKA A et al.: An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer (2003) 39(16):2318-2327.
- DIXON JM, RENSHAW L, YOUNG O et al.: Anastrozole and letrozole an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res. Treat. (2006) 100(Suppl. 1):A105.
- DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. (1998) 16(2):453-461.
- BUDZAR A, DOUMA J, DAVIDSON N et al.: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. (2001) 19(14):3357-3366.
- MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. (2003) 21(11):2101-2109.
- MARCOM PK, ISAACS C, HARRIS L et al.: A phase II trial of letrozole and trastuzumab for ER and/or PR and HER2 positive metastatic breast cancer: final results. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):S27 (Abstract # 596).
- TRAINA TA, RUGO H, CARAVELLI J et al.: Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):S133 (Abstract # 3050).
- FISHER B, DIGNAM J, BRYANT J et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. (1996) 88(21):1529-1542.
- GOSS PE, INGLE JN, MARTINO S et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. (2003) 349(19):1793-1802.
- INGLE J, TU D, SHEPHERD L, PALMER M, PATER J, GOSS P: NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):A549.
- GOSS PE, INGLE JN, MARTINO S et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. (2005) 97(17):1262-1271.
- WASAN KM, GOSS PE, PRITCHARD PH et al.: The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann. Oncol. (2005) 16(5):707-715.
- PEREZ EA, JOSSE RG, PRITCHARD KI et al.: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a comparison study to NCIC CTG MA.17. J. Clin. Oncol. (2006) 24(22):3629-3635.
- COATES AS, KESHAVIAH A, THÜRLIMANN B et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. (2007) 25(5):486-492.
- WINER EP, HUDIS C, BURSTEIN HJ et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. (2005) 23(3):619-629.
- GOLDHIRSCH A, GLICK JH, GELBER RD, COATES AS, THÜRLIMANN B, SENN HJ: Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol. (2005) 16(10):1569-1583.
- EIERMANN W, PAEPKE S, APPFELSTAEDT J et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. (2001) 12(11):1527-1532.
- ELLIS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErB-1- and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. (2001) 19(18):3808-3816.
- RENSHAW L, MURRAY J, YOUNG O, CAMERON D, MILLER WR, DIXON JM: Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res. Treat. (2004) 88(Suppl. 1):S36(Abstract # 405).
- GUILLEM V, LLOMBART-CUSSAC A, GUERRERO JL et al.: Clinical response at 4 months to neoadjuvant letrozole predicts distant disease free survival in postmenopausal women with stage II – III ER/PgR-positive breast cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):10531.
- MACASKILL EJ, RENSHAW L, DIXON JM: Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist (2006) 11(10):1081-1088.
- ELLIS MJ, TAO Y, YOUNG O et al.: Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. (2006) 24(19):3019-3025.
- BOYCE SP, MINCEY BA, DUH MS et al.: Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT). Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):S44 (Abstract # 665).
- MINCEY BA: Osteoporosis in women with breast cancer. Curr. Oncol. Rep. (2003) 5(1):53-57.
- FALLOWFIELD L: Acceptance of adjuvant endocrine therapies and quality of life issues. Breast (2005) 14(6):612-616.
- WHELAN TJ, GOSS PE, INGLE JN et al.: Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J. Clin. Oncol. (2005) 23(28):6931-6940.
- BRUFSKY A, HARKER WG, BECK JT et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. (2006) 25(7):829-836.
- YANCIK R, WESLEY MN, RIES LA, HAVLIK RJ, EDWARDS BK, YATES JW: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama (2001) 285(7):885-892.
- FRANKLIN SS, GUSTIN W, WONG ND et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation (1997) 96(1):308-315.
- NILSSON G, HOLMBERG L, GARMO H, TERENT A, BLOMQVIST C: Increased incidence of stroke in women with breast cancer. Eur. J. Cancer (2005) 41(3):423-429.
- MCCLOSKEY E, EASTELL R, LAKNER G, MIYAMOTO A, CLACK G: Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S101 (Abstract # 2052).
- BACHMANN GA: Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J. Reprod. Med. (2005) 50(3):155-165.
- STAROPOLI CA, FLAWS JA, BUSH TL, MOULTON AW: Predictors of menopausal hot flashes. J. Womens Health (1998) 7(9):1149-1155.
- PANDIT L, OUSLANDER JG: Postmenopausal vaginal atrophy and atrophic vaginitis. Am. J. Med. Sci. (1997) 314(4):228-231.
- THURLIMANN B, KESHAVIAH A, COATES AS et al.: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. (2005) 353(26):2747-2757.
- THOMAS RJ, MARSHALL CJ, WILLIAMS M, WALKER LG: Does switching to letrozole improve hot flushes, mood and quality of life in tamoxifen intolerant patients? Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S107 (Abstract # 2067).
- BOTTINI A, GENERALI D, BERUTI A et al.: Primary letrozole therapy versus the combination of letrozole plus oral cyclophosphamide in elderly breast cancer patients: a single institution randomized phase II trial. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):S756 (Abstract # 8108).
- RADICE D, REDAELLI A: Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics (2003) 21(6):383-396.
- BERKOWITZ N, GUPTA S, SILBERMAN G: Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health (2000) 3(1):23-30.
- KARNON J, JOHNSTON SR, JONES T, GLENDENNING A: A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann. Oncol. (2003) 14(11):1629-1633.
- KARNON J, DELEA T, JOHNSTON SR et al.: Cost-effectiveness of letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics (2006) 24(3):237-250.
- OUAGARI KE, KARNON J, DELEA T, TALBOT W, BRANDMANN J: Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res. Treat. (2007) 101(1):37-49.
- DRANITSARIS G, VERMA S, TRUDEA M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. Oncol. (2003) 26(3):289-296.
- DUNN C, KEAM SJ: Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Pharmacoeconomics (2006) 24(5):495-517.
- DELEA TE, KARNON J, SMITH RE et al.: Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am. J. Manag. Care (2006) 12(7):374-386.
- DELEA TE, KARNON J, THOMAS SK et al.: Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective. Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S102 (Abstract # 2054).
Websites
- http://www.cancer.org/downloads/stt/cff2007leadingsites.pdf
- http://www.nccn.org/professionals/physican_gls/PDF/breast.pdf National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology-v.1.2007.
- http://clinicaltrials.gov/ct/show/NCT00382070 A clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer. Registered in ClinicalTrials.gov; NCT00382070.
- http://clinicaltrials.gov/ct/show/NCT00290745 Primary hormonal therapy for ductal carcinoma in situ: exploration of a novel approach to the clinical management of noninvasive breast cancer. Registered in ClinicalTrials.gov; NCT00290745.